MAMC Journal of Medical Sciences

: 2018  |  Volume : 4  |  Issue : 3  |  Page : 116--120

Retinopathy of Prematurity

Mukta Sharma, Arti Sareen, Sunder Singh Negi 
 Department of Ophthalmology, DDU ZH, Shimla, Himachal Pradesh, India

Correspondence Address:
Dr. Mukta Sharma
DDU ZH, Shimla, Himachal Pradesh


Retinopathy of Prematurity (ROP) is a bilateral proliferative retinopathy affecting premature infants with low birth weight,who have been exposed to excessive oxygenation, resulting in dysregulated vascular endothelial growth factor expression and thus untimely vasoobliteration or exaggerated vasoproliferation.Screening for ROP is mandatory in such infants so as to prevent this blinding disorder.

How to cite this article:
Sharma M, Sareen A, Negi SS. Retinopathy of Prematurity.MAMC J Med Sci 2018;4:116-120

How to cite this URL:
Sharma M, Sareen A, Negi SS. Retinopathy of Prematurity. MAMC J Med Sci [serial online] 2018 [cited 2019 Jan 16 ];4:116-120
Available from:

Full Text


Retinopathy of prematurity (ROP), previously known as retrolental fibroplasia, is a bilateral proliferative retinopathy affecting premature infants with low birth weight who have been exposed to high concentration of oxygen. The retinopathy was first reported by Terry[1] in 1942. ROP can be seen in 85% to 90% of children with low birth weight when exposed to high concentration of oxygen.[2] The incidence of ROP in India varies between 24% and 48% in low birth weight infants.[3]


A vanguard of mesenchymal cells initially grows outwards in the nerve fibre layer (NFL) from the region of the optic disc beginning at around 16 weeks of gestation. These mesenchymal cells give rise to retinal capillary endothelial cells, which then form the capillary system. When excessive oxygenation is used in the nursing of premature infants, ex utero changes in oxygen tension cause abnormal up or downregulation of vascular endothelial growth factor (VEGF) expression. Dysregulated VEGF expression leads to untimely vaso-obliteration or exaggerated vasoproliferation. Retinal arteries and eventually the veins are obliterated, inciting a phase of neovascularization and fibrous proliferation, resulting in different stages of ROP.[4] In rare cases, ROP has been found in some patients with a mutation in norrie disease protein (NDP) gene, which is normally associated with Norrie disease.[5],[6]

Various risk factors which contribute to the development of ROP are prematurity, high exposure to oxygen, low birth weight, cardiac defects, and infections.[7],[8]


ROP prevalence varies from 5% to 8% in developed countries to up to 30% in developing countries. ROP is now a public health problem in middle-income countries.[9],[10]

Incidence of ROP is increasing in developing countries including India, because of improved neonatal survival rate. This is referred to as the third epidemic of ROP. Out of 26 million annual live births, approximately 2 million are less than 2000 g in weight and are at risk of developing ROP. In India, approximately one in 1000 children is blind. The incidence of ROP in India varies between 39% and 51.9% in low birth weight infants.

In 2012, WHO published data on rates of preterm birth and the number of premature babies born in different regions of the world. According to this report, premature birth has many different causes, and the prevention is challenging. Prematurity is the most common cause of neonatal death.[11] The first case of the epidemic was seen on St. Valentine’s Day in 1941, when the premature baby in Boston was diagnosed.[12]


International Classification of ROP was developed in 1984, modified in 1987, and revisited in 2005.[13],[14] It takes into account the following:Location of ROP by zoneZone I: Optic disc (OP) at the center and twice the distance between optic disc and the fovea as its radiusZone II: Extends from the zone 1 to the nasal ora serrata anteriorlyZone III: Remaining temporal peripheral retinaExtent of ROP by the number of clock-hours involvedSeverity of ROP by the stageStage 1: The presence of a demarcation line between vascularized and avascularized retinaStage 2: The presence of demarcation ridge that has height, width, and volumeStage 3: A ridge with extraretinal fibrovascular proliferation [[Figure 1]]{Figure 1}Stage 4: Subtotal retinal detachmentExtrafovealRetinal detachment including fovea [[Figure 2]]{Figure 2}Stage 5: Total retinal detachment

Plus disease: It is not a disease different from ROP but is a descriptive term for vascularly active eye with the potential to progress rapidly. It is characterized by the presence of engorged and tortuous vessels in at least two quadrants at the posterior pole with any stage of ROP, along with the vitreous haze [[Figure 3]]. In addition, the anterior segment in plus disease often shows dilated iris vessels [[Figure 4]]. A “+” or “plus” is added following the ROP stage number to designate the presence of plus disease. Stage 3 ROP with plus disease would be written as 3+ ROP.[14]{Figure 3}{Figure 4}

Prethreshold disease: Defined as ROP inZone 1: any stageZone 2: Stage 2 with plus componentZone 2 or 3: Stage 3 with plus component but not reaching threshold clock-hours

It needs very close observation, as it can rapidly progress to threshold disease which needs prompt treatment.

Threshold disease: It is characterized by more than 5 contiguous clock-hours or 8 cumulative clock-hours of extraretinal neovascularization in association with plus disease and location of the retinal vessels within zone 1 or 2 [[Figure 5]]. It is an indication for treatment. It needs laser or cryotherapy in less than 72 h.[15],[16]{Figure 5}

 Screening in India

National Neonatology Forum guidelines for screening are followed in India.[17] According to these guidelines, screening for ROP should be performed in all preterm neonates who are born atGestational age: 34 weeks or less and/orBirth weight: 1750 g or lessAs well as in babies 34 to 36 weeks gestation or 1750 to 2000 g birth weight, if they have risk factors for ROP

 Timing of Screening Examinations

The first retinal examination should be performed not later than 4 weeks of age or 30 days of life in infants born ≥28 weeks of gestational age (30 days rule).Infants born <28 weeks or <1200 g birth weight should be screened early, by 2 to 3 weeks of age, to enable early identification of aggressive posterior (AP)-ROP

Indirect ophthalmoscope with a 28-D condensing lens is used to examine the fundus. Scleral depression is then used to examine the nasal retina, followed by the temporal retina to establish the proximity of retinal vessels to the ora serrata [[Figure 5]].

The standard approach is to assessThe peripapillary vessels to determine whether plus disease is present or notThe status of retinal vascularization by examining the nasal retina to determine if the vessels have reached the nasal ora serrataThe presence and severity of retinopathyThe extent of the retinopathy

Careful determination of these four parameters allows the clinician to assess most accurately the severity of the retinopathy and to develop an appropriate plan for follow-up. It is advisable to screen the baby every 1 week at least until the infant is 38 to 40 weeks of postmenstrual age. Conclusion of the retinal screening examinations should be based on whether full retinal vascularization has occurred or not. This usually occurs at about the 40th week of postmenstrual age and mostly completes by the 45th week.[17],[18],[19]


The ultimate goals of treatment of threshold ROP arePrevention of any retinal detachment or scarringOptimization of visual outcome

 Laser Photocoagulation

Laser has become the instrument of choice. The aim of the treatment is to ablate the entire peripheral avascular retina up to the ora serrata in a near-confluent burn pattern getting as close to the edge of the ridge as possible. Photocoagulation is delivered through a dilated pupil with a 20 or 28-D condensing lens using a portable diode or argon laser with an indirect ophthalmoscope. The endpoint is near-confluent ablation, with burns spaced one-half burn width apart, from the ora serrata up to, but not including the ridge for 360°. The retina should be inspected for skip areas. Treated eyes are evaluated in about a week to consider retreatment. Persistent plus disease or fibrovascular proliferation is an indication for additional treatment.[20],[21],[22]

Indications for utilizing cryotherapy over laser in the management of ROP include poor fundus visibility, lack of availability of laser, or treating physician’s unfamiliarity with indirect laser retinopexy techniques.[23]

Intravitreal injection of injection bevacizumab has been reported as a supportive measure in aggressive progressive ROP.[24],[25],[26],[27]

Oral propanolol is being evaluated for countracting the progression of ROP, but safety is a concern. A study in a mouse model of human ROP has shown that the beta blocker is protective against retinal angiogenesis and ameliorates blood retinal barrier dysfunction.[28],[29]

 Surgical Treatment

Goal of surgical intervention varies with the severity of the detachment for extramacular retinal detachment (stage 4A ROP):Undistorted or posterior poleTotal retinal reattachmentPreservation of the lens

Surgery for stage 4B ROP is performed:To minimize retinal distortion and prevent total detachment (stage 5)The functional goal is ambulatory vision

The surgical techniques for stage 4 include scleral buckling and vitrectomy. The surgical techniques used in stage 5 are confined to:Closed lensectomy and pars plicata vitrectomy with membrane peeling accompanied occasionally by drainage of subretinal fluidOpen-sky vitrectomy with intracapsular lensectomy and membrane peeling has also been used for those eyes in which the anterior segment is clouded and will not allow closed vitrectomy.[30]

The Early Treatment for Retinopathy of Prematurity Cooperative Group sought to reevaluate the timing of intervention in eyes with ROP.[31],[32]

As infants afflicted with ROP have matured, the ophthalmic community has gained experience with “Adult ROP” with early nuclear sclerotic cataract, glaucoma, exudative retinopathy, and rhegmatogenous retinal detachment.

 Future Therapeutic Targets

The discovery of the importance of VEGF and immunoglobulin (Ig1) in the development of ROP is a step forward in our understanding of the pathogenesis of the disease.[33] Investigation of other conditions with incomplete retinal vascularization such as Norrie’s disease, familial exudative vitreoretinopathy, and incontinentia pigmenti might provide insight into the treatment of ROP. One form of VEFR is caused by Frizzled 4 gene defect. Both Norrin (protein product of Norrie disease gene) and Frizzled 4 gene causes similar defects in human and mice with incomplete retinal vascularization and lack of deep retinal vessels.[34],[35],[36] It has been shown that Norrin ligand binds to Frizzled 4, a Wnt receptor, and ectopic Norrin restores retinal vascularization in Norrie’s disease mice. These findings give us a possibility of new pharmacological therapy for eye diseases with incomplete vascularization of peripheral retina.[37] Supplementation with vitamin A, omega-3 fatty acids, and inositol are all exciting arenas for further trials as preliminary data show promising results in ROP prevention.[38]

Strategies for control of ROP: According to guidelines issued by American Academy of Pediatrics[39],[40],[41]:Prevention of premature birthsImproved neonatal careReduce sepsisBetter oxygen monitoring[Arterial oxygen tension at 45 to 80 mmHg with oxygen saturation limits of 85% and 93% for preterm infants with gestational age (GA) <32 weeks]*Regular screening

Thus, collaborative efforts involving the pediatrician, neonatologist, and the ophthalmologist are required to prevent this preventable cause of blindness in children. Failure to diagnose and treat ROP and its complications in a timely fashion increases the legal exposure of physicians caring for children with ROP.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Terry T. Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. Am J Ophthalmol 1942;24:203-4.
2Flynn JT, O’Grady GE, Herrera J, Kushner BJ, Cantolino S, Milam W. Retrolental fibroplasia: I. Clinical observations. Arch Ophthalmol 1977;95:217-23.
3Le C, Basani L, David Z. Retinopathy of prematurity: Incidence, prevalance, risk factors and outcomes in tertiary eye. J Clin Ophthalmol Res 2016;4:119-22.
4Pierce EA, Foley ED, Smith LE. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114:1219-28.
5Dickinson JL, Sale MM, Passmore A, Fitzgerald LM, Wheatley CM, Burdon KP et al. Mutations in the NDP gene: Contribution to Norrie disease, familial exudative vitreoretinopathy and retinopathy of prematurity. Clin Exp Ophthalmol 2006;34:682-8.
6Csak K, Szabo V, Szabo A. Pathogenesis and genetic basis for retinopathy of prematurity. Front Biosci 2006;11:908-20.
7Karna P, Muttineni J, Angel L, Karmaus W. Retinopathy of prematurity and risk factors: A prospective cohort study. BMC Pediatr 2005;5:18.
8Campbell K. Intensive oxygen therapy as a possible cause for retrolental fibroplasias. A clinical approach. Med J Austr 1951;2:48-50.
9Gilbert C, Fielder A, Gordillo L, Quinn G, Semiglia R, Visintin P et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: Implications for screening programs. Pediatrics 2005;115:e518-25.
10Limburg H, Gilbert C, Hon DN, Dung NC, Hoang TH. Prevalance and causes of blindness in children in Vietnam. Ophthalmology 2012;119:355-61.
11World Health Organization. Born too soon: The global action report on preterm birth. Geneva, Switzerland: World Health Organization 2012.
12Silverman WA. The lesson of retrolental fibroplasia. 1977;236:100-7.
13International Committee for the Classification of Retinopathy of Prematurity. The international classification of retinopathy of prematurity revisited. Arch Ophthalmol 2005;123:991-9.
14The Committee for the Classification of Retinopathy of Prematurity. International Committee for Classification of ROP. Arch Ophthalmol 2006;124:1669-70.
15[No authors listed]. Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group. Arch Ophthalmol 1988;106:471-9.
16Repka MX, Palmer EA, Tung B. Involution of retinopathy of prematurity (ROP). Arch Ophthalmol 2000;118:645-9.
17Jalali S, Hussain A, Matalia J, Anand R. Modification of screening criteria for retinopathy of prematurity in India and other middle-income group countries. Am J Ophthalmol 2006;141:966-8.
18Ells A, Holmes JM, Astle WF, Williams G, Leske DA, Fielden M et al. Telemedicine approach to screening for severe retinopathy of prematurity: A pilot study. Ophthalmology 2003;110:2113-7.
19Wilkinson AR, Haines L, Head K, Fielder AR. Retinopathy of prematurity guidelines. Early Hum Dev 2008;84:77-82.
20Laws DE, Morton C, Weindling M, Clark D. Systemic effects of screening of retinopathy of prematurity. Br J Ophthalmol 1996;80:425-8.
21Palmer EA. Treatment of ROP by peripheral retinal ablation. In: Isenberg SJ, editor. The eye in infancy. Chicago: Year Book Medical Publishers 1994. pp 471-7.
22Azad RV, Pal N, Chandra P. Enhanced mydriasis during indirect diode laser therapy for threshold ROP. J Ped Ophthalmology Strabismus 2006;43:54-5.
23Laser ROP Study Group. Laser therapy for retinopathy of prematurity. Arch Ophthalmol 1994;112:154-6.
24Tasman W, Brown G, Schaffer D, Quinn G, Naidoff M, Benson WE et al. Cryotherapy for active retinopathy of prematurity. Ophthalmol 1986;93:580-5.
25Palmer EA, Flynn JT, Hardy RJ. Incidence and early course of retinopathy of prematurity. The Cryotherapy for Retinopathy of Prematurity Cooperative Group. Ophthalmology 1991;98:1628-40.
26Shah PK, Narendran V, Tawansy KA, Raghuram A. Intravitreal bevacizumab for post laser anterior segment ischaemia in aggressive posterior retinopathy of prematurity. Indian J Ophthalmol 2007;55:75-6.
27Geloneck MM, Chuang AZ, Clark WL; BEAT-ROP Cooperative Group. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: A randomized clinical trial. JAMA Ophthalmol 2014;132:1327-33.
28Eldweik L, Mantagos IS. Role of VEGF inhibition in the treatment of retinopathy of prematurity. Semin Ophthalmol 2016;31:163-8.
29Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK. Effects and complications of bevacizumab use in patients with retinopathy of prematurity: A multi center study in Taiwan. Ophthalmology 2011;118:176-83.
30Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 2011;364:603-15.
31Capone Jr A, Trese MT. Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments. Ophthalmology 2001;108:2068-70.
32Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: Results of the Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthamol 2003;121:1684-94.
33Robitaille J, MacDonald ML, Kaykas A, Sheldahl LC, Zeisler J, Dube MP et al. Mutant frizzled-4 disrupts retinal angiogenesis in familial exudative vitreoretinopathy. Nat Genet 2002;32:326-30.
34Rehm HL, Zhang DS, Brown MC, Burgess B, Halpin C, Berger W et al. Vascular defects and sensorineural deafness in a mouse model of Norrie disease. J Neurosci 2002;22:4286-92.
35Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C et al. Vascular development in the retina and inner ear: Control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 2004;116:883-95.
36Niehrs C. Norrin and Frizzled; a new vein for the eye. Dev Cell 2004;6:453-4.
37Ohlmann A, Scholz M, Goldwich A, Chauhan BK, Hudl K, Ohlmann AV et al. Ectopicnorrin induces growth of ocular capillaries and restores normal retinal angiogenesis in Norrie disease mutant mice. J Neurosci 2005;25:1701-10.
38Irina L. Preventive strategy in the management of ROP: A review of literature. Open J Pediatr 2015;5:121-7.
39Dobson V, Quinn GE, Summers CG, Hardy RJ, Tung B, Good WV. Grating visual acuity results in the early treatment for retinopathy of prematurity study. Arch Ophthalmol 2011;129:840-6.
40Shah PK, Prabhu V, Karandikar SS, Ranjan R, Narendran V, Kalpana N. Retinopathy of prematurity: Past, present and future. World J Clin Pediatr 2016;5:35-46.
41Filippi L, Cavallaro G, Bagnoli P, Dal Monte M, Fiorini P, Donzelli G et al. Oral propranolol for ROP.Risks, safety concerns and perspective. J Pediatr 2013 163:1570-7.